Research
Hormonal
GLP-1 receptor agonists and co-agonists were associated with a lower risk of incident atrial fibrillation among individuals with overweight or obesity.
Practitioners may consider GLP-1RAs and co-agonists as potential options for reducing atrial fibrillation risk in overweight or obese patients.
StrongSupportsmedium confidence
Among individuals with overweight or obesity, GLP-1RAs and co-agonists were associated with a lower risk of incident AF event.
Why this rating
The study is a systematic review and meta-analysis of randomized controlled trials.
Source
Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials
Paschalis Karakasis et al. · Metabolism · 2025
Meta-analysisCited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →